Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Хирургическая или транскатетерная замена аортального клапана у пациентов промежуточного хирургического риска
2017-03-17
SCID: 54.1/c9s7cagt
Discuss with AI
Bayesian noninferiority analysisintermediate surgical risksevere aortic stenosissurgical aortic-valve replacementtranscatheter aortic-valve replacement
Figures from the paper
Abstract (AI)
BACKGROUND: Although transcatheter aortic-valve replacement (TAVR) is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. METHODS: We evaluated the clinical outcomes in intermediate-risk patients with severe, symptomatic aortic stenosis in a randomized trial comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement. The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement. We used Bayesian analytical methods (with a margin of 0.07) to evaluate the noninferiority of TAVR as compared with surgical valve replacement. RESULTS: A total of 1746 patients underwent randomization at 87 centers. Of these patients, 1660 underwent an attempted TAVR or surgical procedure. The mean (±SD) age of the patients was 79.8±6.2 years, and all were at intermediate risk for surgery (Society of Thoracic Surgeons Predicted Risk of Mortality, 4.5±1.6%). At 24 months, the estimated incidence of the primary end point was 12.6% in the TAVR group and 14.0% in the surgery group (95% credible interval [Bayesian analysis] for difference, -5.2 to 2.3%; posterior probability of noninferiority, >0.999). Surgery was associated with higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR had higher rates of residual aortic regurgitation and need for pacemaker implantation. TAVR resulted in lower mean gradients and larger aortic-valve areas than surgery. Structural valve deterioration at 24 months did not occur in either group. CONCLUSIONS: TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure. (Funded by Medtronic; SURTAVI ClinicalTrials.gov number, NCT01586910 .).
Key Findings
1
In 1,660 intermediate-risk patients with severe symptomatic aortic stenosis, self-expanding TAVR was noninferior to surgical replacement for death or disabling stroke at 24 months.
2
No structural valve deterioration occurred in either treatment group during 24 months of follow-up.
3
Surgery caused more acute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR caused more residual aortic regurgitation and pacemaker implantation.
4
TAVR produced lower mean transvalvular gradients and larger aortic-valve areas than surgery.
5
The 24-month primary-endpoint incidence was 12.6% after TAVR versus 14.0% after surgery, with a posterior probability of noninferiority greater than 0.999.
Research Object
Severe, symptomatic aortic stenosis in intermediate-surgical-risk patients undergoing aortic-valve replacement
Research Subject
Comparative 24-month clinical outcomes and adverse-event profiles of transcatheter versus surgical aortic-valve replacement
Publication Details
Publication Date
2017-03-17
Journal
Publisher
ISSN
Cited by
3082
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by6
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2021
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association2023
2017 ESC/EACTS Guidelines for the management of valvular heart disease2017
2021 ESC/EACTS Guidelines for the management of valvular heart disease2021
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association2024
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2022